PTC Therapeutics board approves $500M share repurchase program

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that its Board of Directors has authorized a share repurchase program allowing the company to buy back up to $500 million of its outstanding common stock, subject to market conditions.

Under the program, repurchases may be conducted through open-market transactions, pre-set trading plans, privately negotiated transactions, accelerated share repurchases, and other methods permitted under applicable securities laws. Timing and volume of repurchases will be at management's discretion.

Chief Executive Officer Matthew B. Klein, M.D., said, "The share repurchase program reflects our deep conviction in the strength of the Company and the prospects for near- and long-term growth. We are investing in PTC at a time when our shares provide a compelling opportunity while still maintaining the financial flexibility to support existing programs and pursue potential value creative business development transactions."

PTC Therapeutics is a biopharmaceutical company based in Warren, N.J., focused on rare disorders. The announcement was made Nov. 3, 2026, according to a company press release.

You May Also Be Interested In

• Ingram Micro prices secondary offering at $25.90 per share
• Pfizer names Cecile Guegan permanent CFO effective Nov. 1, 2026
• Everforth ECS wins NGA contract extension worth up to $200M